RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure–response relationship

por Nakagawa, Kazuhiko, Garon, Edward B., Gao, Ling, Callies, Sophie, Zimmermann, Annamaria, Walgren, Richard, Visseren-Grul, Carla, Reck, Martin
Publicado 2022

Phase 1 cohort expansion study of LY3023414, a dual PI3K/mTOR inhibitor, in patients with advanced mesothelioma

por Zauderer, Marjorie G., Alley, Evan W., Bendell, Johanna, Capelletto, Enrica, Bauer, Todd M., Callies, Sophie, Szpurka, Anna M., Kang, Suhyun, Willard, Melinda D., Wacheck, Volker, Varghese, Anna M.
Publicado 2021

Molecular Imaging and Pharmacokinetic Analysis of Carbon-11 Labeled Antisense Oligonucleotide LY2181308 in Cancer Patients

por Saleem, Azeem, Matthews, Julian C., Ranson, Malcolm, Callies, Sophie, André, Valérie, Lahn, Michael, Dickinson, Claire, Prenant, Christian, Brown, Gavin, McMahon, Adam, Talbot, Denis C., Jones, Terry, Price, Patricia M.
Publicado 2011

A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia

por Vadhan-Raj, Saroj, Abonour, Rafat, Goldman, Jonathan W., Smith, David A., Slapak, Christopher A., Ilaria, Robert L., Tiu, Ramon V., Wang, Xuejing, Callies, Sophie, Cox, Joanne, Tuttle, Jay L., Lau, Yiu-Keung, Roeland, Eric J.
Publicado 2017

Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III Trials

por Llovet, Josep M., Singal, Amit G., Villanueva, Augusto, Finn, Richard S., Kudo, Masatoshi, Galle, Peter R., Ikeda, Masafumi, Callies, Sophie, McGrath, Louise M., Wang, Chunxiao, Abada, Paolo, Widau, Ryan C., Gonzalez-Gugel, Elena, Zhu, Andrew X.
Publicado 2022

Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer

por Sweeney, Christopher J., Percent, Ivor J., Babu, Sunil, Cultrera, Jennifer L., Mehlhaff, Bryan A., Goodman, Oscar B., Morris, David S., Schnadig, Ian D., Albany, Costantine, Shore, Neal D., Sieber, Paul R., Guba, Susan C., Zhang, Wei, Wacheck, Volker, Donoho, Gregory P., Szpurka, Anna M., Callies, Sophie, Lin, Boris Kin, Bendell, Johanna C.
Publicado 2022

First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer

por Yap, Timothy A., Vieito, Maria, Baldini, Capucine, Sepúlveda-Sánchez, Juan Manuel, Kondo, Shunsuke, Simonelli, Matteo, Cosman, Rasha, van der Westhuizen, Andre, Atkinson, Victoria, Carpentier, Antoine F., Löhr, Mario, Redman, Rebecca, Mason, Warren, Cervantes, Andres, Le Rhun, Emilie, Ochsenreither, Sebastian, Warren, Louise, Zhao, Yumin, Callies, Sophie, Estrem, Shawn T., Man, Michael, Gandhi, Leena, Avsar, Emin, Melisi, Davide
Publicado 2021